Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Weekapaug who wrote (225)	9/11/1998 12:32:00 PM
From: LemurHouse	Read Replies (2) \| Respond to of 656

I think that you well may be called away at 60 next week, but as you say, who knows? In any case you'll have made a nice trade. In addition to the Enbrel approval which is expected next week, the company yesterday announced positive phase III results for a new drug to combat MS. That helped give the stock a lift yesterday, but its down today on news that Hoescht received FDA approval of an RA drug that competes w/Enbrel. I decided to take the opportunity to take a modest long position in IMNX. Cheers.